Engineering Antibody Evolution: Germline‐Targeting HIV Vaccines Reach a Turning Point

Abstract

This commentary examines three recent Nature studies demonstrating a conceptual shift in HIV vaccine design, demonstrating how germline-targeting HIV vaccines can progress beyond expanding rare broad neutralizing antibody (bnAb) precursors to deliberately guiding their affinity maturation into bnAbs in non-human primates.